CD274 and cancer: In particular, immune checkpoint blockade has transformed the landscape of cancer immunotherapy, demonstrating unprecedented clinical efficacy in more than 15 cancer types, including NSCLC, through the use of programmed death 1 (PD1) and programmed death 1 ligand (PDL1).